Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $417,543.50 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Jared Gollob sold 4,895 shares of Kymera Therapeutics stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $85.30, for a total transaction of $417,543.50. Following the sale, the insider owned 117,134 shares in the company, valued at approximately $9,991,530.20. This trade represents a 4.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jared Gollob also recently made the following trade(s):

• On Monday, March 2nd, Jared Gollob sold 5,613 shares of Kymera Therapeutics stock. The stock was sold at an average price of $88.93, for a total transaction of $499,164.09.
• On Monday, December 8th, Jared Gollob sold 49,307 shares of Kymera Therapeutics stock. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $83.49 on Friday. The stock has a fifty day moving average of $78.80 and a 200-day moving average of $66.80. The stock has a market capitalization of $6.82 billion, a P/E ratio of -22.69 and a beta of 2.20. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The company had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same period last year, the company earned ($0.88) EPS. The business’s revenue for the quarter was down 60.8% compared to the same quarter last year. Equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026), kept a “Buy” rating and reiterated a $134 price target — this reinforces constructive analyst sentiment and supports buying interest. Read More.
• Positive Sentiment: UBS and several peers have raised price targets (UBS to $128, Barclays/Oppenheimer/Mizuho also higher), signaling consensus analyst optimism around Kymera’s pipeline progress as a medium‑term catalyst. Read More.
• Positive Sentiment: Another outlet reported a price‑target bump to $100 — additional upward target revisions help underpin sentiment even as valuation remains tied to clinical milestones. Read More.
• Positive Sentiment: Coverage highlights a healthy cash runway (~$1.6B reported) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are the primary value drivers for this clinical‑stage biotech. Read More.
• Neutral Sentiment: Technical/contextual note — KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analyst average targets remain well above current levels, which can amplify momentum in either direction. Read More.
• Negative Sentiment: Large director sale: Director Bruce Booth sold 81,866 shares (~$7.38M at ≈$90), a material single‑day disposal that can be perceived as profit‑taking and may cap short‑term upside. Read More.
• Negative Sentiment: Multiple senior insiders (CFO Bruce Jacobs, COO Jeremy Chadwick, Jared Gollob and others) disclosed sales across March 2–4 at roughly $85–$89, each trimming holdings by a few percent — repeated insider selling increases short‑term supply and investor caution. Read More.

Institutional Investors Weigh In On Kymera Therapeutics

A number of hedge funds have recently made changes to their positions in KYMR. Federated Hermes Inc. acquired a new stake in shares of Kymera Therapeutics in the 3rd quarter worth $31,622,000. China Universal Asset Management Co. Ltd. increased its holdings in Kymera Therapeutics by 77.2% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock worth $1,007,000 after buying an additional 10,052 shares during the period. Candriam S.C.A. raised its holdings in shares of Kymera Therapeutics by 24.4% during the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock worth $10,847,000 after purchasing an additional 37,536 shares during the last quarter. Frontier Capital Management Co. LLC raised its stake in shares of Kymera Therapeutics by 272.7% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after buying an additional 359,847 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH lifted its holdings in Kymera Therapeutics by 26.3% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after acquiring an additional 22,392 shares during the period.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several research analyst reports. Mizuho upped their price objective on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. Stifel Nicolaus set a $114.00 price target on Kymera Therapeutics in a research note on Monday, December 8th. BTIG Research decreased their target price on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. Oppenheimer lifted their price target on Kymera Therapeutics from $67.00 to $120.00 and gave the company an “outperform” rating in a research note on Tuesday, December 9th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.